pioglitazone has been researched along with Asymmetric Diabetic Proximal Motor Neuropathy in 17 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To define the components of the metabolic syndrome that contribute to diabetic polyneuropathy (DPN) in type 2 diabetes mellitus (T2DM), we treated the BKS db/db mouse, an established murine model of T2DM and the metabolic syndrome, with the thiazolidinedione class drug pioglitazone." | 3.81 | The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes. ( Backus, C; Brosius, FC; Dauch, JR; Feldman, EL; Hayes, JM; Hinder, LM; Hur, J; Kretzler, M; Pennathur, S, 2015) |
| "Rats were tested for thermal hyperalgesia and mechanical allodynia." | 1.56 | Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ. ( El-Gawly, HW; El-Sherbeeny, NA; Elaidy, SM; Elkholy, SE; Toraih, EA, 2020) |
| " Therefore, we tested the hypothesis that chronic administration of pioglitazone would reduce PDN in Zucker Diabetic Fatty (ZDF(fa/fa) [ZDF]) rats." | 1.43 | Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes. ( Adkins, BG; Anderson, KL; Donahue, RR; Griggs, RB; Taylor, BK; Thibault, O, 2016) |
| "Chronic pain is a common complication of diabetes." | 1.42 | Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments. ( Byrne, FM; Chapman, V; Cheetham, S; Vickers, S, 2015) |
| "Treatment of pioglitazone lowered blood glucose level and prevented delay of MNCV in SDT fatty rats." | 1.38 | Diabetic peripheral neuropathy in Spontaneously Diabetic Torii-Lepr(fa) (SDT fatty) rats. ( Kemmochi, Y; Matsushita, M; Mera, Y; Ohta, T; Sasase, T; Sato, E; Tadaki, H; Tomimoto, D; Yamaguchi, T, 2012) |
| "Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes)." | 1.31 | Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. ( Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 5 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, DFS | 1 |
| Donahue, RR | 2 |
| Laird, DE | 1 |
| Oliveira, MCG | 1 |
| Taylor, BK | 2 |
| Elkholy, SE | 1 |
| Elaidy, SM | 1 |
| El-Sherbeeny, NA | 1 |
| Toraih, EA | 1 |
| El-Gawly, HW | 1 |
| Ponirakis, G | 2 |
| Abdul-Ghani, MA | 2 |
| Jayyousi, A | 2 |
| Almuhannadi, H | 2 |
| Petropoulos, IN | 2 |
| Khan, A | 2 |
| Gad, H | 2 |
| Migahid, O | 2 |
| Megahed, A | 2 |
| DeFronzo, R | 2 |
| Mahfoud, Z | 2 |
| Hassan, M | 1 |
| Al Hamad, H | 1 |
| Ramadan, M | 1 |
| Alam, U | 1 |
| Malik, RA | 2 |
| Bakkar, NZ | 1 |
| Mougharbil, N | 2 |
| Mroueh, A | 2 |
| Kaplan, A | 2 |
| Eid, AH | 2 |
| Fares, S | 1 |
| Zouein, FA | 2 |
| El-Yazbi, AF | 2 |
| Zirie, MA | 1 |
| Al-Mohannadi, S | 1 |
| Qazi, M | 1 |
| AlMarri, F | 1 |
| Al-Khayat, F | 1 |
| Shokrzadeh, M | 1 |
| Mirshafa, A | 1 |
| Yekta Moghaddam, N | 1 |
| Birjandian, B | 1 |
| Shaki, F | 1 |
| Al-Assi, O | 1 |
| Ghali, R | 1 |
| de Anda-Jáuregui, G | 1 |
| Guo, K | 1 |
| McGregor, BA | 1 |
| Feldman, EL | 3 |
| Hur, J | 3 |
| Jin, HY | 1 |
| Lee, KA | 1 |
| Wu, JZ | 1 |
| Baek, HS | 1 |
| Park, TS | 1 |
| Byrne, FM | 1 |
| Cheetham, S | 1 |
| Vickers, S | 1 |
| Chapman, V | 1 |
| Dauch, JR | 1 |
| Hinder, LM | 2 |
| Hayes, JM | 1 |
| Backus, C | 1 |
| Pennathur, S | 2 |
| Kretzler, M | 2 |
| Brosius, FC | 2 |
| Griggs, RB | 1 |
| Adkins, BG | 1 |
| Anderson, KL | 1 |
| Thibault, O | 1 |
| Park, M | 1 |
| Rumora, AE | 1 |
| Eichinger, F | 1 |
| Hempe, J | 1 |
| Elvert, R | 1 |
| Schmidts, HL | 1 |
| Kramer, W | 1 |
| Herling, AW | 1 |
| Yamaguchi, T | 1 |
| Sasase, T | 1 |
| Mera, Y | 1 |
| Tomimoto, D | 1 |
| Tadaki, H | 1 |
| Kemmochi, Y | 1 |
| Ohta, T | 1 |
| Sato, E | 1 |
| Matsushita, M | 1 |
| Ota, T | 1 |
| Osawa, K | 1 |
| Kürthy, M | 1 |
| Mogyorósi, T | 1 |
| Nagy, K | 1 |
| Kukorelli, T | 1 |
| Jednákovits, A | 1 |
| Tálosi, L | 1 |
| Bíró, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)[NCT00244244] | Phase 2 | 80 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pioglitazone and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Exenatide; Glycated Hemoglobin; Hum | 2020 |
Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.
Topics: Cornea; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Exenatide; Female; Glycated Hemoglobin; Gl | 2021 |
15 other studies available for pioglitazone and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
The PPARγ agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy.
Topics: Analgesics; Animals; Diabetic Neuropathies; Disease Models, Animal; Female; Hyperalgesia; Male; Mice | 2022 |
Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ.
Topics: Animals; Behavior, Animal; Comorbidity; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet | 2020 |
Worsening baroreflex sensitivity on progression to type 2 diabetes: localized vs. systemic inflammation and role of antidiabetic therapy.
Topics: Animals; Baroreflex; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2020 |
Mitochondrial dysfunction contribute to diabetic neurotoxicity induced by streptozocin in mice: protective effect of Urtica dioica and pioglitazone.
Topics: Animals; Antioxidants; Biomarkers; Brain; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dr | 2018 |
Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs.
Topics: Animals; Diabetic Cardiomyopathies; Diabetic Neuropathies; Dietary Fats; Energy Intake; Glucose Into | 2018 |
Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone.
Topics: Animals; Diabetic Neuropathies; Mice; Models, Biological; Pioglitazone; Systems Biology | 2019 |
The neuroprotective benefit from pioglitazone (PIO) addition on the alpha lipoic acid (ALA)-based treatment in experimental diabetic rats.
Topics: Animals; Axons; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drug Therapy, | 2014 |
Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.
Topics: Animal Feed; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neu | 2015 |
The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes.
Topics: Animals; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Models, Animal; Hypo | 2015 |
Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.
Topics: Administration, Oral; Analgesics; Animals; Central Nervous System Sensitization; Cold Temperature; D | 2016 |
Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease.
Topics: Animals; Computational Biology; Diabetic Nephropathies; Diabetic Neuropathies; Gene Expression Profi | 2017 |
Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications.
Topics: Animals; Blood Chemical Analysis; Caloric Restriction; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2012 |
Diabetic peripheral neuropathy in Spontaneously Diabetic Torii-Lepr(fa) (SDT fatty) rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Model | 2012 |
Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
Topics: Body Weight; Charcot-Marie-Tooth Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; | 2003 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; | 2002 |